Use of a novel non‐steroidal anti‐inflammatory drug in the horse

Higgins, A.J.; Lees, P.; Sedgwick, A. D.; Buick, A.R.; Churchus, R.

doi:10.1111/j.2042-3306.1987.tb02584.x

Cited by 10 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Samples of inflammatory exudate (1.5 mL) were collected 1, 3,5,8,12,24,30 and 36 h after administration of BAY Y 1015 or placebo into tubes containing 10 mg BW 540C (Wellcome Foundation, now Glaxo Wellcome Research and Development, Stevenage, Herts., UK) for measurement of LTB 4 concentration, leukocyte count and exudate concentration of BAY Y 1015. BW 540C is a dual cyclo-oxygenase/5-lipoxygenase inhibitor used to prevent artefactual eicosanoid generation in vitro following sample collection (Copp et al, 1984;Higgins et al, 1987). Samples of transudate (1.5 mL) for measurement of BAY Y 1015 concentration were harvested at the same time points from tissue cages that were not stimulated by addition of carrageenan.…”

Section: Pharmacodynamics and Pharmacokinetics Of Bay Y 1015mentioning

confidence: 99%

Pharmacology of the 5‐lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse

Cunningham

Andrews

Landoni

et al. 1997

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

Calcium ionophore A23187 induced time and concentration dependent production of immunoreactive leukotriene (LT) B4 by equine heparinized whole blood in vitro. Time dependent production of immunoreactive LTB4 by equine neutrophils and immunoreactive LTC4 by equine eosinophils in vitro was also demonstrated. The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dependent inhibition of ionophore-induced LTB4 synthesis by equine whole blood (mean +/- SEM IC50s n = 5; 6.14 +/- 0.28 microM vs. 12.30 +/- 0.75 microM for BAY Y 1015 and BAY X 1005, respectively) and neutrophils (mean +/- SEM IC50s n = 5; 0.003 +/- 0.001 microM vs. 0.045 +/- 0.021 microM for BAY Y 1015 and BAY X 1005, respectively) and LTC4 synthesis by equine eosinophils (mean +/- SEM IC50s n = 5; 0.0036 +/- 0.0002 microM and 0.108 +/- 0.023 microM for BAY Y 1015 and BAY X 1005, respectively) in vitro. In all three assays, BAY Y 1015 was more potent than BAY X 1005, and for both compounds much higher concentrations were required to inhibit LT synthesis by whole blood compared to isolated neutrophils and eosinophils. Plasma concentration-time relationships and pharmacokinetic parameters for BAY Y 1015 administered intravenously and orally to six horses at a dosage of 10 mg/kg in a two period cross-over study were established. The study also evaluated the anti-inflammatory properties of BAY Y 1015 and its ability to inhibit ex vivo whole blood LTB4 synthesis and in vivo LTB4 synthesis in a tissue cage model of acute inflammation. At this dosage, BAY Y 1015 failed to significantly inhibit immunoreactive LTB4 synthesis or the oedema produced by intradermal injection of the mild irritant, carrageenan.

show abstract

Section: Pharmacodynamics and Pharmacokinetics Of Bay Y 1015mentioning

confidence: 99%

Pharmacology of the 5‐lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse

Cunningham

Andrews

Landoni

et al. 1997

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…When it comes to using IRT to prove the effectiveness of NSAIDs, there is a relative scarcity of studies in horses. Some studies have used IRT to assess the vascular component of the inflammatory response and examine the effects of anti-inflammatory drugs on experimentally induced acute inflammation ( 35 , 36 ). Recent studies have induced systemic inflammation by administering LPS intravenously and used IRT to evaluate the effectiveness of NSAIDs by analyzing the temperature of the hoof wall of horses ( 25 , 37 ).…”

Section: Introductionmentioning

confidence: 99%

Functional infrared thermography imaging can be used to assess the effectiveness of Maxicam Gel® in pre-emptively treating transient synovitis and lameness in horses

Carvalho,

Del Puppo,

Littiere

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

IntroductionDiagnosing and treating lameness in horses is essential to improving their welfare. In equine orthopedic practice, infrared thermography (IRT) can indirectly detect soreness. Non-steroidal anti-inflammatory drugs can treat painful and inflammatory processes in horses. Using IRT, the efficacy of meloxicam (Maxicam Gel®) was evaluated in pre-treating transient synovitis in horses induced by a middle carpal joint injection of lipopolysaccharides (LPS) from E. coli 055:B5 at a dose of 10 endotoxin units.MethodsIn a cross-over design, six healthy horses were randomly assigned to receive either 0.6 mg/kg of oral Maxicam Gel® (MAXVO) or a mock administration (control group, C) following a two-week washout period. IRT of the middle carpal joint, visual lameness assessment and joint circumference were recorded over time. Clinical and hematological evaluations were performed. Synovial fluid aspirates were analyzed for total nucleated cell count, total protein, and prostaglandin E2. A mixed effects analysis of variance was performed for repeated measures over time, followed by Tukey’s test. A multinomial logistic regression was conducted to determine whether there is a relationship between a thermography temperature change and the lameness score.ResultsThere were no changes in joint circumference. The MAXVO group showed a lower rectal temperature 4 h after synovitis induction. The C group presented an increase in neutrophils and a decrease in total hemoglobin and hematocrit 8 h after induction. No changes were observed in the synovial fluid between groups. The horses that received meloxicam did not show clinically significant lameness at any time, while the C group showed an increase in lameness 2, 4, and 8 h after synovitis induction.DiscussionIRT indicated that the skin surface temperature of the middle carpal joint was lower in horses who received meloxicam, suggesting a reduction in the inflammatory process induced by LPS. It was observed that the maximum temperature peaks in the dorsopalmar and lateropalmar positions can be utilized to predict the severity of lameness, particularly when the temperature rises above 34°C. Horses pre-treated with meloxicam showed either reduced or no indication of mild to moderate pain and presented a lowehr thermographic temperature, which indicates the effectiveness of Maxicam Gel® as an anti-inflammatory.

show abstract

Non-steroidal anti-inflammatory drugs

Kollias-Baker¹,

Cox²

2004

Equine Clinical Pharmacology

View full text Add to dashboard Cite

Use of a novel non‐steroidal anti‐inflammatory drug in the horse

Cited by 10 publications

References 22 publications

Pharmacology of the 5‐lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse

Pharmacology of the 5‐lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse

Functional infrared thermography imaging can be used to assess the effectiveness of Maxicam Gel® in pre-emptively treating transient synovitis and lameness in horses

Non-steroidal anti-inflammatory drugs

Contact Info

Product

Resources

About